直接肾素抑制剂阿利吉仑治疗高血压病的研究进展  

Research advances in direct renin inhibitor aliskiren for the treatment of hypertension

作　　者：王飞宇[1] 白元[1] 蔡亚梅[2] 秦永文[1] 

机构地区：[1]第二军医大学长海医院心血管内科,上海200433 [2]第二军医大学药学院药物分析学教研室,上海200433

出　　处：《药学服务与研究》2014年第2期118-121,共4页Pharmaceutical Care and Research

摘　　要：阿利吉仑是第一个用于临床的口服直接肾素抑制剂。临床试验表明,其降压效果与氯沙坦、厄贝沙坦、赖诺普利、雷米普利等一线降压药相当,与血管紧张素转化酶抑制药(ACEI)、血管紧张素Ⅱ受体拮抗药(ARB)、钙通道阻滞药(CCB)或利尿剂等联合使用时降压作用增强。另外,阿利吉仑具有一定的心脏保护作用,且安全性和耐受性良好。本文简要综述了阿利吉仑在治疗高血压病方面的研究进展。Aliskiren is the first orally taken direct rennin inhibitor （DRI） for clinical application. Clinical trials have demonstrated that its pressure reduction effect was equivalent to those of the first line pressure reduction drugs, such as h）sar tan, irbesartan, lisinopril and ramipril. When it is used in combination with angiotensin converting enzyme inhibitors （ACEI）, angiotensin receptor blockers （ARB）, calcium channel blockers （CCB） or diuretics, its pressure reduction effect could further be enhanced. In addition, aliskiren has certain cardio-protective effect, with good safety and tolerability. This review briefly introduces research progress of aliskiren in the treatment of hypertension.

关 键 词：肾素抑制剂 阿利吉仑 高血压病 综述 

分 类 号：R972.4[医药卫生—药品]